Mecapegfilgrastim(PEG-G-CSF) for Prophylaxis of Chemotherapy-induced Neutropenia in Patients With Lymphoma

Jilin University

Status and phase: Enrolling; Phase 2

Conditions: Chemotherapy-induced Neutropenia; Lymphoma

Treatments: Drug: rhG-CSF; Drug: Pegylated rhG-CSF

Study type: Interventional

Funder types: Other

Identifiers

NCT04460508

mecapegfilgrastim-lym-2020-1

Details and patient eligibility

About

Neutropenia is one of the most frequent adverse effects of chemotherapy, and the main factor to limit the dosage and the continuation of chemotherapy.A newly pegylated rhG-CSF was independently developed by JIANGSU HENGRUI Medicine Co., Ltd, China. Phase 1a, 1b and phase 2 trials have shown that pegylated rhG-CSF has decreased renal clearance, increased plasma half-life, and prolonged efficacy in compare with filgrastim.

This study is to evaluate efficacy and safety in chemotherapy-induced neutropenia of once-per-cycle Mecapegfilgrastim Injection(PEG-G-CSF) and daily G-CSF in Patients with lymphoma patients.

Full description

This is a randomized, controlled study. A total of 170 lymphoma patients who are eligible are planned to randomized assigned into two groups to receive mecapegfilgrastim fixed dose of 6 mg or filgrastim 5 µg/kg/day during chemotherapy.

The primary endpoint is the duration of grade ≥3 neutropenia in cycle 1. The secondary endpoints include incidence of grade ≥3 neutropenia and febrile neutropenia (FN) in cycle 1-4, The pharmacoeconomics and safety profile are also evaluated.

Enrollment: 170 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age 18 to 75 years;
2. Patients with primary malignant lymphoma confirmed by histopathology or immunomolecular biology and requiring treatment with multi-cycle high-intensity chemotherapy regimen;
3. ECOG performance status ≤ 1;
4. ANC ≥1.5×109/L, PLT≥80×109 /L, Hb≥ 75g/L, WBC ≥3.0×109/L;
5. Subjects with pregnancy ability must agree to use reliable contraceptive measures from screening to 1 year after treatment;
6. Patients must sign informed consent and be willing and able to comply with the requirements of visits, treatment, laboratory tests and other research requirements stipulated in the research schedul.

Exclusion criteria

1. Lymphoma central involvement;
2. Recipients of hematopoietic stem cell transplantation or organ transplantation;
3. Currently conducting clinical trials of other drugs;
4. There is an uncontrollable infection with body temperature ≥38℃;
5. liver function examination: total bilirubin (TBIL., alanine aminotransferase (ALT. and ascetic aminotransferase (AST. were all 2.5 times the upper limit of the normal value of >; if they were caused by liver metastasis, the upper limit of the normal value of > was 5 times;Renal function test: serum creatinine (Cr. >2 times the upper limit of normal value
6. Patients with serious chronic diseases of heart, kidney, liver and other important organs;
7. Patients with severe uncontrolled diabetes;
8. Pregnant or lactating female patients.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

170 participants in 2 patient groups

Mecapegfilgrastim

Experimental group

Description:

Patients were administered pegylated rhG-CSF 6mg once at the 3rd day of every chemotherapy cycle.

Treatment:

Drug: Pegylated rhG-CSF

rhG-CSF

Active Comparator group

Description:

Patients were administered pegylated rhG-CSF 6 ug/kg/day from the 3rd day of every chemotherapy cycle.

Treatment:

Drug: rhG-CSF